迪哲醫藥(688192.SH):擬使用不超16.30億元閒置募集資金進行現金管理
格隆匯12月20日丨迪哲醫藥(688192.SH)公佈,公司於2021年12月20日召開第一屆董事會第七次會議、第一屆監事會第七次會議,審議通過了《關於使用暫時閒置募集資金進行現金管理的議案》,同意公司使用最高額度不超過人民幣16.30億元(含本數)的暫時閒置募集資金進行現金管理,用於投資安全性高、流動性好的銀行理財產品或存款類產品或券商收益憑證(包括但不限於保本型理財產品、協定性存款、結構性存款、定期存款、大額轉讓存單、券商收益憑證等)。使用期限自本次董事會審議通過之日起12個月內,在前述額度及決議有效期內,資金可以循環滾動使用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.